What to watch at ESMO; Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs

Taking stock of the drug industry, from the lab to the medicine chest

October 19, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer Here are the presentations we'll be keeping an eye on at this year's conference of the European Society for Medical Oncology. By Andrew Joseph STAT+ | Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs John Maraganore shared thoughts on how entrepreneurs can prepare for the rough-and-tumble world of drug development and raise money. By Jonathan Wosen STAT+ | The future of Biogen: Pragmatism, 'a few moonshots,' and no Twinkies CEO Christopher Viehbacher said Biogen's future will rely on taking a more disciplined approach to risk than in the past. By Damian Garde STAT Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award "I was always the one saying, 'don't forget about GLP-1' and challenging decisions at the company," Knudsen recalls. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser